PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 23, 2026Drug Delivery and Translational Research3 citationsOpen Access

Formulation considerations in enhancing olfactory mucosal deposition for nose-to-brain drug delivery

View Full Paper
ADAnisha DSouzaMassachusetts Eye and Ear InfirmaryMKMaayan S. KahanMassachusetts Eye and Ear InfirmaryAYAlicia YangIcahn School of Medicine at Mount Sinai

Key Points

  • To analyze formulation strategies that improve drug delivery to the brain via the olfactory mucosa.
  • Review of physiological and anatomical barriers to olfactory drug targeting
  • Discussion of nanoparticle and polymer-based strategies
  • Evaluation of in vitro, ex vivo, and in vivo delivery models
  • Identification of challenges in mucosal deposition and retention
  • Highlighting mucoadhesive polymers and nanocarriers as effective agents
  • Insight into emerging technologies and regulatory considerations for N2B therapeutics

Abstract

Abstract Nose-to-brain (N2B) drug delivery offers a promising alternative to circumvent the blood–brain barrier and deliver therapeutic agents directly to the central nervous system. Among the intranasal pathways, targeting the olfactory mucosa is particularly attractive due to its direct anatomical and functional connection to the brain. However, effective deposition and retention of drug-loaded formulations in the olfactory region remain significant challenges, owing to complex nasal anatomy, mucociliary clearance, and limited surface area. This review critically examines the physiological and anatomical barriers to olfactory targeting and highlights recent advances in nanoparticle-based strategies designed to enhance mucosal deposition and transport. Various formulation approaches—including mucoadhesive polymers, surface-functionalized nanocarriers, and stimuli-responsive systems—are discussed alongside innovative delivery devices and administration techniques tailored for olfactory mucosal delivery. In vitro, ex vivo, and in vivo models used to evaluate these strategies are reviewed, as are safety, regulatory, and translational considerations. Finally, the review explores emerging technologies such as patient-specific delivery platforms and smart nanoparticles, offering a forward-looking perspective on the future of N2B therapeutics for neurological disorders. Graphical abstract

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

DSouza et al. (2026) studied this question.

synapsesocial.com/papers/69c08bb5a48f6b84677f95cfhttps://doi.org/10.1007/s13346-026-02097-7
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1An Adverse Outcome Pathway for Decreased Lung Function Focusing on Mechanisms of Impaired Mucociliary Clearance Following Inhalation Exposure2021 · 22 citations
  2. 2RPMI 2650 epithelial model and three-dimensional reconstructed human nasal mucosa as in vitro models for nasal permeation studies2009 · 138 citations
  3. 3Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia2016 · 198 citations
  4. 4The nasal cavity and its olfactory sensory territories2015 · 2 citations
  5. 5Applications of Focused Ultrasound for the Treatment of Glioblastoma: A New Frontier2022 · 95 citations